Kezar Life Sciences Analyst Ratings
Kezar Life Sciences Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/27/2023 | 2104.83% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 11/14/2023 | 120.48% | Wells Fargo | $4 → $2 | Maintains | Equal-Weight |
| 10/12/2023 | 2104.83% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 10/05/2023 | — | JonesTrading | Downgrades | Buy → Hold | |
| 09/25/2023 | 2104.83% | HC Wainwright & Co. | $18 → $20 | Maintains | Buy |
| 08/11/2023 | — | Wells Fargo | Downgrades | Overweight → Equal-Weight | |
| 08/11/2023 | 1884.34% | HC Wainwright & Co. | $19 → $18 | Maintains | Buy |
| 05/12/2023 | 1994.58% | HC Wainwright & Co. | $21 → $19 | Maintains | Buy |
| 05/12/2023 | 1333.14% | Wells Fargo | $14 → $13 | Maintains | Overweight |
| 03/16/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 03/16/2023 | 2215.07% | HC Wainwright & Co. | → $21 | Reiterates | → Buy |
| 01/03/2023 | 1443.38% | Wells Fargo | $17 → $14 | Maintains | Overweight |
| 08/12/2022 | 2215.07% | HC Wainwright & Co. | $20 → $21 | Maintains | Buy |
| 06/28/2022 | 1774.1% | Wells Fargo | $13 → $17 | Maintains | Overweight |
| 05/13/2022 | 1333.14% | Wells Fargo | $14 → $13 | Maintains | Overweight |
| 05/04/2022 | 1443.38% | Wells Fargo | $19 → $14 | Maintains | Overweight |
| 03/18/2022 | 2325.31% | HC Wainwright & Co. | $20 → $22 | Maintains | Buy |
| 12/08/2021 | 1994.58% | Wells Fargo | → $19 | Initiates Coverage On | → Overweight |
| 11/16/2021 | 2104.83% | HC Wainwright & Co. | $12 → $20 | Maintains | Buy |
| 07/20/2021 | 1443.38% | JonesTrading | → $14 | Initiates Coverage On | → Buy |
| 06/04/2020 | 1222.9% | HC Wainwright & Co. | $9 → $12 | Maintains | Buy |
| 05/05/2020 | 892.17% | HC Wainwright & Co. | $15 → $9 | Reiterates | → Buy |
| 03/13/2020 | 1884.34% | Wells Fargo | $30 → $18 | Maintains | Overweight |
| 07/29/2019 | 1553.62% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/27/2023 | 2104.83% | HC Wainwright & Co. | → 20 美元 | 重申 | 购买 → 购买 |
| 11/14/2023 | 120.48% | 富国银行 | 4 美元 → 2 美元 | 维护 | 重量相等 |
| 2023 年 12 月 10 日 | 2104.83% | HC Wainwright & Co. | → 20 美元 | 重申 | 购买 → 购买 |
| 10/05/2023 | — | JonesTrading | 降级 | 买入 → 持有 | |
| 09/25/2023 | 2104.83% | HC Wainwright & Co. | 18 美元 → 20 美元 | 维护 | 买 |
| 08/11/2023 | — | 富国银行 | 降级 | 超重 → 重量相等 | |
| 08/11/2023 | 1884.34% | HC Wainwright & Co. | 19 美元 → 18 美元 | 维护 | 买 |
| 05/12/2023 | 1994.58% | HC Wainwright & Co. | 21 美元 → 19 美元 | 维护 | 买 |
| 05/12/2023 | 1333.14% | 富国银行 | 14 美元 → 13 美元 | 维护 | 超重 |
| 03/16/2023 | — | 威廉布莱尔 | 降级 | 跑赢大盘 → 市场表现 | |
| 03/16/2023 | 2215.07% | HC Wainwright & Co. | → 21 美元 | 重申 | → 购买 |
| 01/03/2023 | 1443.38% | 富国银行 | 17 美元 → 14 美元 | 维护 | 超重 |
| 2022 年 12 月 8 日 | 2215.07% | HC Wainwright & Co. | 20 美元 → 21 美元 | 维护 | 买 |
| 06/28/2022 | 1774.1% | 富国银行 | 13 美元 → 17 美元 | 维护 | 超重 |
| 05/13/2022 | 1333.14% | 富国银行 | 14 美元 → 13 美元 | 维护 | 超重 |
| 05/04/2022 | 1443.38% | 富国银行 | 19 美元 → 14 美元 | 维护 | 超重 |
| 03/18/2022 | 2325.31% | HC Wainwright & Co. | 20 美元 → 22 美元 | 维护 | 买 |
| 2021 年 8 月 12 日 | 1994.58% | 富国银行 | → 19 美元 | 启动覆盖范围开启 | → 超重 |
| 11/16/2021 | 2104.83% | HC Wainwright & Co. | 12 美元 → 20 美元 | 维护 | 买 |
| 2021 年 7 月 20 日 | 1443.38% | JonesTrading | → 14 美元 | 启动覆盖范围开启 | → 购买 |
| 06/04/2020 | 1222.9% | HC Wainwright & Co. | 9 美元 → 12 美元 | 维护 | 买 |
| 05/05/2020 | 892.17% | HC Wainwright & Co. | 15 美元 → 9 美元 | 重申 | → 购买 |
| 03/13/2020 | 1884.34% | 富国银行 | 30 美元 → 18 美元 | 维护 | 超重 |
| 07/29/2019 | 1553.62% | HC Wainwright & Co. | → 15 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for Kezar Life Sciences (KZR)?
Kezar Life Sciences (KZR) 的目标价格是多少？
The latest price target for Kezar Life Sciences (NASDAQ: KZR) was reported by HC Wainwright & Co. on November 27, 2023. The analyst firm set a price target for $20.00 expecting KZR to rise to within 12 months (a possible 2104.83% upside). 12 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月27日公布了Kezar Life Sciences（纳斯达克股票代码：KZR）的最新目标股价。该分析公司将目标股价定为20.00美元，预计KZR将在12个月内升至12个月（可能上涨2104.83％）。去年有12家分析公司公布了评级。
What is the most recent analyst rating for Kezar Life Sciences (KZR)?
Kezar Life Sciences（KZR）的最新分析师评级是多少？
The latest analyst rating for Kezar Life Sciences (NASDAQ: KZR) was provided by HC Wainwright & Co., and Kezar Life Sciences reiterated their buy rating.
HC Wainwright & Co. 提供了Kezar Life Sciences（纳斯达克股票代码：KZR）的最新分析师评级，Kezar Life Sciences重申了买入评级。
When is the next analyst rating going to be posted or updated for Kezar Life Sciences (KZR)?
Kezar Life Sciences（KZR）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kezar Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kezar Life Sciences was filed on November 27, 2023 so you should expect the next rating to be made available sometime around November 27, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Kezar Life Sciences的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Kezar Life Sciences的最新评级是在2023年11月27日发布的，因此您应该预计下一个评级将在2024年11月27日左右公布。
Is the Analyst Rating Kezar Life Sciences (KZR) correct?
分析师对 Kezar Life Sciences (KZR) 的评级正确吗？
While ratings are subjective and will change, the latest Kezar Life Sciences (KZR) rating was a reiterated with a price target of $0.00 to $20.00. The current price Kezar Life Sciences (KZR) is trading at is $0.91, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但重申了最新的Kezar Life Sciences（KZR）评级，目标股价为0.00美元至20.00美元。Kezar Life Sciences（KZR）目前的交易价格为0.91美元，在分析师的预测区间内。